Gilead Sciences (NASDAQ: GILD) received a Hold rating from Robert W. Baird analyst Brian Skorney today. The company’s shares closed yesterday at $78.92.
According to TipRanks.com, Skorney is a 4-star analyst with an average return of 11.0% and a 57.1% success rate. Skorney covers the Healthcare sector, focusing on stocks such as Melinta Therapeutics Inc, Reata Pharmaceuticals, and Sarepta Therapeutics.
Gilead Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $86.70.
See today’s analyst top recommended stocks >>
Gilead Sciences’ market cap is currently $102.6B and has a P/E ratio of 30.35. The company has a Price to Book ratio of 4.98.
Based on the recent corporate insider activity of 84 insiders, corporate insider sentiment is negative on the stock. Earlier this month, John C. Martin, a Director at GILD sold 50,000 shares for a total of $3,540,168.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
